45-minute detection & differentiation of Clostridium difficile & the Epidemic 027 strain
The alarming rise in the incidence of Clostridium difficile infection (CDI) highlights the need for rapid and accurate diagnostic solutions. Today’s testing methodologies have forced clinicians to choose between solutions that deliver either speed or accuracy.
Xpert® C. difficile delivers both:
- Sensitivity of current available rapid diagnostic tests are unacceptably low1
- Additional length of stay increase caused by C. difficile infection is 5.6 days1
- Incremental costs due to C. difficile infection can be as high as $7,1791 per patient
Management of CDI requires rapid and accurate diagnosis. Cepheid’s Xpert C. difficile delivers both while enabling clinicians to optimize patient management and reduce length of stay.
(1) Sloan et al., JCM 2008
Today’s testing methodologies have forced clinicians to choose between solutions that deliver either speed or accuracy. Cepheid’s 45-minute Xpert C. difficile delivers both:
- Superior test accuracy eliminates the need for additional or repeat testing
- Rapid identification of infected patient helps infection control efforts
- Timely reporting enables clinicians to administer appropriate therapy thereby improving patient management
Cepheid’s Xpert C. difficile test provides on-demand results you can trust and empowers your clinical team to better manage patients.
Xpert® C. difficile
Number of Tests: 10Catalog #: GXCDIFFICILE-10
Cepheid's One-Hour PCR Technology
Cepheid’s one-hour PCR technology enabled VAMC Houston to quickly identify and isolate MRSA colonized and C. difficile positive patients resulting in lower HAI rates.
Ephraim McDowell Regional Medical Center
Ephraim McDowell Regional Medical Center improves adherence to optimized testing protocols for C. difficile resulting in lower C. difficile rates and decreased patient time in isolation.
White Paper: Supporting CDC’s Four Core Actions to Fight Antimicrobial Resistance
CDC has declared the complex problem of antimicrobial resistance (AMR) a serious threat today, which will result in potential catastrophic consequences with continued inaction. To combat AMR, the CDC has identified 4 core actions, all of which can be addressed through rapid molecular diagnostics: